General Information
Montelukast sodium is an orally active compound that belongs to a class of molecules termed leukotriene receptor antagonists (LTRAs) and is approved for the treatment of symptoms related to asthma and allergic rhinitis (hay fever). It is also prescribed to prevent exercise-induced bronchospasm. Montelukast sodium inhibits the binding of leukotrienes (molecules secreted by white blood cells) to a receptor that triggers an inflammatory response. Due to its mechanism of action, this drug is not prescribed for the treatment of acute asthma attacks.
About the API
Systematic name
2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2- hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetic acid Trade
Technology
Synthetic
Molecular Formula
C35H35ClNNaO3S
Molecular Weight
608.17 g/mol
Physical properties
off-white to pale yellow colored powder
Therapeutic category
Respiratory
Available formulations
Oral Liquid
Oral Solid
Oral Solid Long-Acting
Regulations
CEP
EU DMF
Japan DMF
Korea DMF
US DMF
CEP
EU DMF
Japan DMF
Korea DMF
US DMF